Titre:
  • Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Auteur:Ingle, James N; Tu, Dongsheng; Pater, Joseph L; Martino, S; Robert, Nicholas J; Muss, Hyman B; Piccart-Gebhart, Martine; Castiglione, Monica; Shepherd, L; Pritchard, Kathleen; Livingston, Robert; Davidson, Nancy E; Norton, Larry; Perez, Edith A; Abrams, Jeffrey S; Cameron, David A; Palmer, Michael J; Goss, Paul E
Informations sur la publication:Breast cancer research and treatment, 99, 3, page (295-300)
Statut de publication:Publié, 2006-10
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Adjuvant hormonal therapy
Early breast cancer
MeSH keywords:Aged
Antineoplastic Agents -- administration & dosage
Antineoplastic Agents -- therapeutic use
Aromatase Inhibitors -- administration & dosage
Aromatase Inhibitors -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- mortality
Breast Neoplasms -- pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Double-Blind Method
Drug Administration Schedule
Female
Humans
Middle Aged
Nitriles -- administration & dosage
Nitriles -- therapeutic use
Postmenopause
Proportional Hazards Models
Receptors, Estrogen -- analysis
Receptors, Progesterone -- analysis
Selective Estrogen Receptor Modulators -- therapeutic use
Survival Analysis
Tamoxifen -- therapeutic use
Time Factors
Treatment Outcome
Triazoles -- administration & dosage
Triazoles -- therapeutic use
Note générale:Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0167-6806
info:doi/10.1007/s10549-006-9207-y
info:scp/33746896140
info:pmid/16541302